IMMNOV Stock Overview
A diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.65 |
| 52 Week High | SEK 3.15 |
| 52 Week Low | SEK 0.53 |
| Beta | 2.38 |
| 1 Month Change | 9.08% |
| 3 Month Change | -29.46% |
| 1 Year Change | -63.86% |
| 3 Year Change | -99.08% |
| 5 Year Change | -99.64% |
| Change since IPO | -97.81% |
Recent News & Updates
Recent updates
Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation
Apr 20
We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate
Dec 09Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?
May 13Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation
Jan 18We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth
Aug 28What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?
Mar 09Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation
Feb 03
Shareholder Returns
| IMMNOV | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -0.2% | 0.4% | -2.7% |
| 1Y | -63.9% | -8.1% | 4.6% |
Return vs Industry: IMMNOV underperformed the Swedish Medical Equipment industry which returned -8.1% over the past year.
Return vs Market: IMMNOV underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| IMMNOV volatility | |
|---|---|
| IMMNOV Average Weekly Movement | 17.6% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: IMMNOV's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IMMNOV's weekly volatility has decreased from 25% to 18% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 9 | Jeff Borcherding | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) Fundamentals Summary
| IMMNOV fundamental statistics | |
|---|---|
| Market cap | SEK 110.14m |
| Earnings (TTM) | -SEK 128.63m |
| Revenue (TTM) | SEK 632.00k |
174.3x
P/S Ratio-0.9x
P/E RatioIs IMMNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMNOV income statement (TTM) | |
|---|---|
| Revenue | SEK 632.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 632.00k |
| Other Expenses | SEK 129.26m |
| Earnings | -SEK 128.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 100.00% |
| Net Profit Margin | -20,353.01% |
| Debt/Equity Ratio | 0% |
How did IMMNOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 10:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immunovia AB (publ) is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Juan Pedro Rodríguez Serrate | Edison Investment Research |
| Alexandru Cogut | Kempen & Co. NV |